Back to Results

Vericel Corp Ord (VCEL)

Vericel Corp. is a U.S.-listed common equity on Nasdaq representing Vericel Corporation, a commercial-stage biopharmaceutical company focused on cellular therapies and specialty biologic products. Its business is centered on sports medicine and severe burn care in North America. The company’s marketed products include MACI for cartilage repair in the knee, Epicel for patients with deep burns, and NexoBrid, a product used for eschar removal in burn treatment. Vericel was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. It was previously known as Aastrom Biosciences, Inc. before adopting its current name in 2014.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-VCEL
$48.28
20.6% Upside
Undervalued
$60.57
51.4% Upside
Bargain
Great
0.0%
November 11, 2026
84.6x
5.5x
6.7x
2.049 B
1.916 B
4.3%
98.8%
9.4
254.6%
Valuation • Fair Value

Vericel Corp Ord (NASDAQ-VCEL) Fair Value by Valuation Model

Review the available estimates for Vericel Corp Ord (NASDAQ-VCEL), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$48.28

Estimated upside of 20.6% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$55.10

Discounted cash flow valuation reference.

Ben Graham Formula Value

$5.25

Classic Ben Graham valuation formula reference.

Comps Fair Value

$41.46

Comparable-company valuation reference.

Analyst Price Target

$60.57

Analysts imply upside of 51.4%.

How to read these valuation models

Use the 6 available valuation references for Vericel Corp Ord (NASDAQ-VCEL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Vericel Corp Ord (NASDAQ-VCEL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

306.3 M

Current operating scale indicator.

Revenue Forecast

335.7 M

Forward revenue estimate.

EBITDA

31.154 M

Current operating profitability reference.

EBITDA Forecast

90.02 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Vericel Corp Ord (NASDAQ-VCEL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Vericel Corp Ord (NASDAQ-VCEL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.69

No elevated caution signal from this screen.

Altman Z-Score

9.4

Relatively strong balance-sheet zone.

FCF / Net Income

254.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Vericel Corp Ord (NASDAQ-VCEL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Vericel Corp Ord (NASDAQ-VCEL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

54

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Vericel Corp Ord (NASDAQ-VCEL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Vericel Corp Ord (NASDAQ-VCEL) Stock Forecast & Technical Outlook

Review Vericel Corp Ord (NASDAQ-VCEL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Vericel Corp Ord (NASDAQ-VCEL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Vericel Corp Ord (NASDAQ-VCEL) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Vericel Corp Ord (NASDAQ-VCEL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Vericel Corp Ord (NASDAQ-VCEL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Vericel Corp Ord (NASDAQ-VCEL) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Vericel Corp Ord (NASDAQ-VCEL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Vericel Corp Ord (NASDAQ-VCEL) has a Strong Buy consensus, with 7 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 1
Sell 0
FAQ • Fast Investor Answers

Vericel Corp Ord (NASDAQ-VCEL) Stock FAQ

Data-supported answers about Vericel Corp Ord (NASDAQ-VCEL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$48.28
Estimated upside 20.6%
Valuation Rating
Undervalued
Estimated upside of 20.6%
Analyst Target
$60.57
Implied upside 51.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Vericel Corp Ord (NASDAQ-VCEL) is $48.28. This implies an estimated upside of 20.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 20.6% versus the current market price.

The available analyst price target for Vericel Corp Ord (NASDAQ-VCEL) is $60.57. The analyst target implies estimated upside of 51.4%.

The current financial health read for Vericel Corp Ord (NASDAQ-VCEL) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Vericel Corp Ord (NASDAQ-VCEL) is November 11, 2026.

The latest available data indicates no current dividend yield for Vericel Corp Ord (NASDAQ-VCEL).

The current P/E ratio listed for Vericel Corp Ord (NASDAQ-VCEL) is 84.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Vericel Corp Ord is 2.049 B.

The current enterprise value listed for Vericel Corp Ord is 1.916 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Vericel Corp Ord is NASDAQ-VCEL, and the stock is listed on NASDAQ.

Vericel Corp Ord (NASDAQ-VCEL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Vericel Corp Ord is 4.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Vericel Corp Ord is 98.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B